J Korean Med Sci.  2021 Nov;36(46):e311. 10.3346/jkms.2021.36.e311.

Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine

Affiliations
  • 1Division of Infectious Diseases, Department of Internal Medicine, Myongji Hospital, Goyang, Korea
  • 2Seegene Medical Foundation, Seoul, Korea
  • 3Department of Laboratory Medicine, Myongji Hospital, Goyang, Korea
  • 4Department of Pediatrics, Myongji Hospital, Goyang, Korea

Abstract

Background
ChAdOx1 and BNT162b2 vaccines are currently commonly used against coronavirus disease 2019 worldwide. Our study was designed to determine the serostatus and relative levels of anti-S and neutralizing antibodies in patients who were administered either ChAdOx1 or BNT162b2 vaccine. In addition, we investigated whether the antibody response to each vaccine differed according to sex and age.
Methods
Healthcare workers (HCWs) at a general hospital who were vaccinated with two doses of either ChAdOx1 or BNT162b2 were invited to participate in this prospective cohort study. Blood samples of HCWs vaccinated with both ChAdOx1 doses over a period of 12 weeks were collected at weeks 4 and 8 post first vaccination and 2 weeks post second vaccination. Blood samples of HCWs vaccinated with BNT162b2 were collected in the third week after the first dose, and the second dose was then administered on the same day; two weeks post second dose (5 weeks after the first dose), blood samples were collected to assess the antibody response. The titers of anti-S antibodies against the severe acute respiratory syndrome coronavirus 2 spike (S) protein receptor-binding domain and the neutralizing antibodies in the collected blood were evaluated.
Results
Of the 309 HCWs enrolled in the study, 205 received ChAdOx1 and 104 received BNT162b2. Blood samples from participants receiving either the ChAdOx1 or BNT162b2 vaccine exhibited substantial anti-S and neutralizing antibody seropositivity subsequent to the second dose. All participants (100%) from both vaccine groups were seropositive for anti-S antibody, while 98% (201/205) of ChAdOx1-vaccinated individuals and 100% (104/104) of BNT162b2-vaccinated individuals were seropositive for neutralizing antibodies. The median levels of anti-S and neutralizing antibodies were significantly higher in the BNT162b2-vaccinated group than the ChAdOx1-vaccinated group; in particular, anti-S antibody titers of 1,020 (interquartile range, 571.0–1,631.0) U/mL vs. 2,360 (1,243–2,500) U/mL, P < 0.05, were recorded for the ChAdOx1 and BNT162b2 groups, respectively, and neutralizing antibody titers of 85.0 (65.9–92.1%) vs. 95.8 (94.4–96.6%), P < 0.05, were recorded for the ChAdOx1 and BNT162b2 groups, respectively. In the ChAdOx1 vaccine group, the neutralizing antibody level was significantly higher in women than in men (85.7 [70.3–92.5%] vs. 77.7 [59.2–91.0%], P < 0.05); however, the neutralizing antibody titer in the BNT162b2 vaccine group did not vary between the two sexes (95.9 [95.2–96.6%] vs. 95.2 [93.5–96.3%], P = 0.200). Analysis of the correlation of antibody profiles with age revealed that the levels of anti-S antibodies and signal inhibition rate (SIR) of neutralizing antibodies decreased significantly with age.
Conclusion
Both the ChAdOx1- and BNT162b2-vaccinated groups showed high seropositivity for anti-S and neutralizing antibodies. The SIR of neutralizing antibodies in the ChAdOx1 vaccine group was higher in women than in men. Enhanced antibody responses were observed in participants vaccinated with BNT162b2 compared to those vaccinated with the ChAdOx1 vaccine.

Keyword

SARS-CoV-2; COVID-19 Vaccine; Antibody; Immunogenicity

Figure

  • Fig. 1 Comparison of antibody responses between ChAdOx1 and BNT162b2 vaccinees. Antibody titers after 1st and 2nd doses of ChAdOx1 and BNT162b2 vaccines are shown.SIR = signal inhibition rate.

  • Fig. 2 Antibody responses after 1st and 2nd dose in ChAdOx1 vaccinees. The antibody titers showed no significant difference at 4 and 8 weeks after the first dose but increased markedly after the second dose of ChAdOx1 vaccine.NS = not significant, SIR = signal inhibition rate.

  • Fig. 3 The correlation between SARS-CoV-2 anti-S antibodies (U/mL) and neutralization rate (%). SARS-CoV-2 anti-S antibody and neutralizing antibody titers showed a strong positive correlation (Pearson's r = 0.89).SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

  • Fig. 4 Difference in anti-S titers and neutralizing antibody titers between two sexes. After the 2nd dose of ChAdOx1 vaccine, the neutralizing antibody titer was higher in females than in males. Regarding the BNT162b2 vaccine, after the 1st dose, the levels of anti-S and neutralizing antibodies were higher in females than in males, but there was no difference in the antibody titers between the sexes after the 2nd dose.NS = not significant, SIR = signal inhibition rate.

  • Fig. 5 Level of anti-S and neutralizing antibodies according to the age. (A) In ChAdOx1 vaccine group, the neutralizing antibody titer was slightly higher in the younger age group than in older age group after the second dose. In the BNT162b2 group, there was no significant difference in the antibody response according to age after the second dose. (B) For anti-S and neutralizing antibody, the antibody levels of individuals are plotted against patient age in both vaccine groups with the best fit lines, Pearson's correlation (R) and P value (P). In both vaccine groups, neutralization tended to decrease with age.SIR = signal inhibition rate.


Reference

1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020; 383(27):2603–2615. PMID: 33301246.
Article
2. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467–478. PMID: 32702298.
3. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021; 396(10267):1979–1993. PMID: 33220855.
4. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med. 2020; 383(25):2439–2450. PMID: 33053279.
Article
5. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021; 384(15):1412–1423. PMID: 33626250.
Article
6. Kim JY, Bae S, Park S, Kwon JS, Lim SY, Park JY, et al. Comparison of antibody and T cell responses induced by single doses of ChAdOx1 nCoV-19 and BNT162b2 vaccines. Immune Netw. 2021; 21(4):e29. PMID: 34522442.
Article
7. Shrotri M, Fragasz E, Geismar C, Nguyen V, Beale S, Braithwaite I, et al. Spike-antibody responses following first and second doses of ChAdOx1 and BNT162b2 vaccines by age, gender, and clinical factors - a prospective community cohort study (Virus Watch). medRxiv. Forthcoming. 2021; DOI: 10.1101/2021.05.12.21257102.
Article
8. Schwarz T, Tober-Lau P, Hillus D, Helbig ET, Lippert LJ, Thibeault C, et al. Delayed antibody and T-cell response to BNT162b2 vaccination in the elderly, Germany. Emerg Infect Dis. 2021; 27(8):2174–2178. PMID: 34102097.
Article
9. Müller L, Andrée M, Moskorz W, Drexler I, Walotka L, Grothmann R, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis. 2021; ciab381. PMID: 33906236.
Article
10. Jung J. Preparing for the coronavirus disease (COVID-19) vaccination: evidence, plans, and implications. J Korean Med Sci. 2021; 36(7):e59. PMID: 33619920.
Article
11. Korea Disease Control and Prevention Agency. Plan KNC-V. Updated 2021. Assessed February 2021. http://www.kdca.go.kr/index.es?sid=a3 .
12. Campi-Azevedo AC, Peruhype-Magalhāes V, Coelho-Dos-Reis JG, Antonelli LR, Costa-Pereira C, Speziali E, et al. 17DD yellow fever revaccination and heightened long-term immunity in populations of disease-endemic areas, Brazil. Emerg Infect Dis. 2019; 25(8):1511–1521. PMID: 31298654.
Article
13. Cohen BJ, Doblas D, Andrews N. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination. Vaccine. 2008; 26(50):6392–6397. PMID: 18834911.
Article
14. Eyal O, Olshevsky U, Lustig S, Paran N, Halevy M, Schneider P, et al. Development of a tissue-culture-based enzyme-immunoassay method for the quantitation of anti-vaccinia-neutralizing antibodies in human sera. J Virol Methods. 2005; 130(1-2):15–21. PMID: 16024096.
Article
15. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020; 38(9):1073–1078. PMID: 32704169.
Article
16. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020; 181(2):281–292.e6. PMID: 32155444.
Article
17. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021; 21(2):73–82. PMID: 33340022.
Article
18. Salvatori G, Luberto L, Maffei M, Aurisicchio L, Roscilli G, Palombo F, et al. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines. J Transl Med. 2020; 18(1):222. PMID: 32493510.
Article
19. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A. 2004; 101(26):9804–9809. PMID: 15210961.
Article
20. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004; 10(8):871–875. PMID: 15247913.
Article
21. Huang WC, Zhou S, He X, Chiem K, Mabrouk MT, Nissly RH, et al. SARS-CoV-2 RBD neutralizing antibody induction is enhanced by particulate vaccination. Adv Mater. 2020; 32(50):e2005637. PMID: 33111375.
Article
22. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205–1211. PMID: 34002089.
Article
23. Kim N, Minn D, Park S, Roh EY, Yoon JH, Park H, et al. Positivity of SARS-CoV-2 antibodies among Korean healthy healthcare workers 1 and 2 weeks after second dose of Pfizer-BioNTech vaccination. J Korean Med Sci. 2021; 36(21):e158. PMID: 34060264.
Article
24. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021; 39(32):4423–4428. PMID: 34210573.
Article
25. Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med. 2020; 12(559):eabc3103. PMID: 32817357.
Article
26. Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, et al. Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients. J Infect Dis. 2021; 223(3):389–398. PMID: 33140086.
Article
27. Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019; 41(2):239–249. PMID: 30547182.
Article
28. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016; 16(10):626–638. PMID: 27546235.
Article
29. Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019; 32(2):e00084-18. PMID: 30867162.
Article
30. Bunders MJ, Altfeld M. Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions. Immunity. 2020; 53(3):487–495. PMID: 32853545.
Article
31. Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell. 2015; 14(3):309–321. PMID: 25720438.
Article
32. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020; 588(7837):315–320. PMID: 32846427.
33. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017; 33(1):577–599. PMID: 28992436.
Article
34. McCartney PR. Sex-based vaccine response in the context of COVID-19. J Obstet Gynecol Neonatal Nurs. 2020; 49(5):405–408.
Article
35. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY). 2020; 12(10):9959–9981. PMID: 32470948.
Article
36. Mahase E. COVID-19: single dose of Pfizer or AstraZeneca vaccine produces strong antibody response in over 80s. BMJ. 2021; 373(979):n979. PMID: 33858846.
Article
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr